U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
TAFASITAMAB
QQA9MLH692
US Approved Rx (2020)
First approved in 2020
General
Names
12
Classification
3
Identifiers
11
Subunits
4
Related Substances
1
TAFASITAMAB
QQA9MLH692
US Approved Rx (2020)
First approved in 2020
General
Approval Year
2020
691
Names
12
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
MOR-00208
Preferred Name
English
TAFASITAMAB
Official Name
English
TAFASITAMAB [MI]
Common Name
English
MOR-208
Common Name
English
XMAB5574
Common Name
English
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Classification
3
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of diffuse large B-cell lymphoma
FDA ORPHAN DRUG
456014
Positive
EU ORPHAN DRUG
Positive
Treatment of IgG4-related disease
EU-Orphan Drug
EU/3/17/1962
Designated
ORPHAN DRUG
Designated
Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
FDA ORPHAN DRUG
427914
Showing 1 to 3 of 3 entries
Previous
1
Next
Identifiers
11
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
WIKIPEDIA
Tafasitamab
PRIMARY
SMS_ID
100000183311
PRIMARY
DRUG BANK
DB15044
PRIMARY
CAS
1422527-84-1
PRIMARY
RXCUI
2387211
PRIMARY
Showing 1 to 5 of 11 entries
Previous
1
2
3
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
QQA9MLH692
TAFASITAMAB
